Article
Oncology
Jiang-Min Zhou, Chen-Yang Zhou, Xiao-Ping Chen, Zhi-Wei Zhang
Summary: In patients with tumors ranging from 2-5 cm, anatomic resection (AR) can effectively remove peritumoral microvascular invasion (MVI) by obtaining a wide surgical margin, reducing postoperative recurrence, and improving prognosis.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2021)
Article
Oncology
Changying Shi, Yong Li, Li Geng, Weifeng Shen, Chengjun Sui, Binghua Dai, Jiongjiong Lu, Mianshun Pan, Jiamei Yang
Summary: This study aimed to investigate the efficacy of SBRT targeting suboptimal resection margin as adjuvant therapy in MVI-positive HCC. The results showed that SBRT group had significantly better DFS and OS compared to the surgery alone group.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Jianwei Liu, Guokun Zhuang, Shilei Bai, Zhiliang Hu, Yong Xia, Caixia Lu, Jie Wang, Chunyan Wang, Liu Liu, Fengwei Li, Yeye Wu, Feng Shen, Kui Wang
Summary: This study investigated the impact of surgical margin and hepatic resection on prognosis for patients with hepatocellular carcinoma (HCC). The results showed that for patients with MVI-positive HCC, wide margins and anatomical resection were protective factors for prognosis, with wide margins being more important. In clinical practice, ensuring wide margins should be prioritized.
Article
Oncology
Haoyu Hu, Shuo Qi, Silue Zeng, Peng Zhang, Linyun He, Sai Wen, Ning Zeng, Jian Yang, Weiqi Zhang, Wen Zhu, Nan Xiang, Chihua Fang
Summary: The study established a predictive model to forecast the occurrence of microvascular invasion in HCC patients, and compared the efficacy of anatomic resection and non-anatomic resection for hepatocellular carcinoma. The predictive model was found to be convenient and accurate, highlighting the importance of performing anatomic resection in patients with high risk of MVI or low risk of MVI with larger tumors.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Kai Zhang, Changcheng Tao, Tana Siqin, Jianxiong Wu, Weiqi Rong
Summary: This study successfully developed and validated a predictive model for early relapse after R0 resection in HCC patients with MVI, incorporating preoperative blood markers, hepatitis status, tumor characteristics, and other factors, with higher predictive accuracy in the validation cohort.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Article
Oncology
Shilei Bai, Lei Hu, Jianwei Liu, Minmin Sun, Yanfu Sun, Feng Xue
Summary: This study investigated the potential effect of postoperative adjuvant therapy with lenvatinib on the long-term prognosis of hepatitis B virus-related hepatocellular carcinoma with microvascular invasion (MVI). The results showed that patients who received postoperative lenvatinib had improved recurrence rates and survival rates compared to those who did not receive the treatment. Nomograms were also used to accurately predict long-term survival.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Shilei Bai, Pinghua Yang, Yanping Wei, Jie Wang, Caixia Lu, Yong Xia, Anfeng Si, Baohua Zhang, Feng Shen, Yexiong Tan, Kui Wang
Summary: This study aimed to establish prediction models for postoperative survival in hepatitis B virus-related hepatocellular carcinoma (HBV-HCC) with microvascular invasion (MVI). Nomograms for disease recurrence and overall survival (OS) were developed using preoperative serological indicators, tumor clinicopathologic features, surgical margin, and postoperative adjuvant TACE. The nomograms showed good predictive performance and accurately stratified patients into different risk groups.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Anwei Mo, Biquan Lin, Denglin Chen
Summary: This study aims to investigate the impact of sequential transcatheter arterial chemoembolization (TACE) on the prognosis of patients with hepatocellular carcinoma (HCC) and microvascular invasion (MVI) following radical resection. Thirteen articles were included in the study, and the results showed that TACE after radical hepatectomy resection (HR) significantly improved the recurrence-free survival (RFS) and overall survival (OS) rates at 1 year, 2 years, 3 years, and 5 years compared to HR alone. The findings suggest that postoperative sequential TACE treatment can benefit patients with HCC and MVI in terms of long-term survival.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Ying-Yi Qin, Wei-Jun Wang, Xiu-Ping Zhang, Yi-Tao Zheng, Yun-Feng Shan, Wen-Ming Cong, Hui Dong, Wan Yee Lau, Shu-Qun Cheng
Summary: This study aimed to establish a novel classification of microvascular invasion (MVI) for predicting prognosis in hepatocellular carcinoma (HCC) patients after RO liver resection (LR). The classification, developed using multivariate cox regression analysis, included factors such as alpha-fetoprotein level, liver cirrhosis, tumor characteristics, and MVI features. The classification system categorized patients into three distinct survival groups and showed higher predictive accuracy compared to other commonly used classifications.
Article
Medicine, Research & Experimental
Yi Wang, Gui-Qi Zhu, Rui Yang, Cheng Wang, Wei-Feng Qu, Tian-Hao Chu, Zheng Tang, Chun Yang, Li Yang, Chang-Wu Zhou, Geng-Yun Miao, Wei-Ren Liu, Ying-Hong Shi, Meng-Su Zeng
Summary: This study revealed the interactions of cell subpopulations and distinct metabolism profiles in MVI+ HCC, and discovered the radiomics features related to the infiltration of APOE(+) macrophages and iCAFs. Furthermore, the study developed Radscore for predicting MVI and HCC prognostication, which could predict the level of infiltration of APOE(+) macrophages and iCAFs.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Yunfei Zhang, Chun Yang, Ruofan Sheng, Yongming Dai, Mengsu Zeng
Summary: This study used restricted spectrum imaging (RSI) to noninvasively identify microvascular invasion (MVI) in hepatocellular carcinoma (HCC), and established a nomogram-based model to predict MVI. The results showed that RSI-derived metrics can be used to efficiently identify MVI in HCC, with potential for prognostic prediction and clinical management.
ACADEMIC RADIOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Yunfei Zhang, Jiejun Chen, Chun Yang, Yongming Dai, Mengsu Zeng
Summary: Habitat imaging based on DWI can accurately predict the microvascular invasion of hepatocellular carcinoma preoperatively. By characterizing cellular density, perfusion, and heterogeneity, different habitats within the tumor can be identified and quantified for predicting MVI with high accuracy.
EUROPEAN RADIOLOGY
(2023)
Article
Oncology
Alexey Surov, Maciej Pech, Jazan Omari, Frank Fischbach, Robert Damm, Katharina Fischbach, Maciej Powerski, Borna Relja, Andreas Wienke
Summary: The study found that minimum ADC reflects tumor grading in HCC, while both minimum ADC and D can predict MVI in HCC. Therefore, these DWI parameters should be estimated for pretreatment tumor stratification in each HCC lesion.
Review
Oncology
Jian Li, Xin Su, Xiao Xu, Changchun Zhao, Ang Liu, Liwen Yang, Baoling Song, Hao Song, Zihan Li, Xiangyong Hao
Summary: Hepatocellular carcinoma (HCC) is a common and deadly tumor globally. Microvascular invasion (MVI) is a major risk factor for recurrence and poor prognosis in HCC patients after surgical resection. Accurate preoperative prediction of MVI status is crucial for clinicians in choosing treatment options and improving overall survival. Various indicators in serology (including liquid biopsies) and imaging have been identified as effective predictors of MVI occurrence, and a multi-indicator model based on deep learning greatly improves prediction accuracy. Additionally, certain genes and proteins have been identified as risk factors tightly associated with MVI occurrence. This review evaluates predictors and risk factors, providing guidance for future research on more accurate predictive methods and the conversion of risk factors into reliable predictors.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Review
Oncology
Er-lei Zhang, Qi Cheng, Zhi-yong Huang, Wei Dong
Summary: The article evaluates the impact of current MVI status on surgical outcomes after curative therapies for HCC patients and emphasizes the urgent need for an international consensus on the validated definition of MVI in order to provide a more consistent evaluation and reliable prediction of surgical outcomes.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Junhua Jin, Xiaojuan Niu, Lihui Zou, Lin Li, Shugang Li, Jingli Han, Peiying Zhang, Jinghai Song, Fei Xiao
Article
Surgery
Xiaojuan Niu, Jinghai Song, Xiuwen He, Jian Chen, Jingyong Xu, Zhe Li, Haikong Long, Junmin Wei
INDIAN JOURNAL OF SURGERY
(2018)
Article
Immunology
Jinghai Song, Hiroshi Hagiya, Haruto Kurata, Hirotaka Mizuno, Toshinori Ito
TRANSPLANT IMMUNOLOGY
(2012)
Article
Biochemistry & Molecular Biology
Kai Yan, Yong Fu, Nan Zhu, Zhuo Wang, Jin-ling Hong, Yao Li, Wei-jing Li, Hai-bin Zhang, Jing-hai Song
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
(2019)
Article
Endocrinology & Metabolism
Min Liu, Shuo Xie, Weiwei Liu, Jingjin Li, Chao Li, Wei Huang, Hexin Li, Jinghai Song, Hong Zhang
JOURNAL OF ENDOCRINOLOGY
(2020)
Article
Oncology
Rui Li, Shibo Song, Xiuwen He, Xiaolei Shi, Zhen Sun, Zhe Li, Jinghai Song
CANCER MANAGEMENT AND RESEARCH
(2020)
Review
Endocrinology & Metabolism
Zhenhua Lu, Yao Li, Jinghai Song
DIABETES METABOLIC SYNDROME AND OBESITY-TARGET & THERAPY
(2020)
Article
Medicine, General & Internal
Zhen Sun, Zhenhua Lu, Rui Li, Weiwe Shao, Yangyan Zheng, Xiaolei Shi, Yao Li, Jinghai Song
Summary: This study identified immunoautophagy-related genes in HCC patients and established a prognostic model based on CANX and HDAC1. The risk score was found to be an independent prognostic factor, with higher scores in the young group and in patients with poorly differentiated tumors. The model showed potential prognostic value and implications for targeted therapy.
INTERNATIONAL JOURNAL OF GENERAL MEDICINE
(2021)
Article
Medicine, Research & Experimental
Kai Yan, Jinghai Song, Xiaojuan Niu, Qi An, Yao Li, Wenzheng Shi, Jianye Wang
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
(2017)
Article
Immunology
C. Matsuda, T. Ito, J. Song, T. Mizushima, H. Tamagawa, Y. Kai, Y. Hamanaka, M. Inoue, T. Nishida, H. Matsuda, Y. Sawa
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
(2007)
Article
Immunology
J. Song, T. Ito, C. Matsuda, M. Tanemura, T. Nishida, M. Nozawa, Y. Sawa
TRANSPLANTATION PROCEEDINGS
(2006)
Article
Immunology
J. Song, T. Ito, C. Matsuda, G. Miao, M. Tanemura, T. Nishida, M. Nozawa, H. Matsuda, Y. Sawa
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
(2006)
Article
Oncology
Rui Li, Zhen Sun, Shibo Song, Xiuwen He, Xiaolei Shi, Zhe Li, Jinghai Song
CANCER MANAGEMENT AND RESEARCH
(2020)
Article
Pharmacology & Pharmacy
Jinghai Song, Chu Matsuda, Yasuyuki Kai, Toshirou Nishida, Kiyokazu Nakajima, Tsunekazu Mizushima, Miki Kinoshita, Tokutaro Yasue, Yoshiki Sawa, Toshinori Ito
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(2008)